Biotricity announced its direct-to-consumer heart health screening service, HeartSecure, is now available for purchase online at HeartSecure. Heart disease remains the leading cause of death worldwide, with someone succumbing to cardiovascular disease every 1.5 seconds. In the United States alone, 127 million adults have at least one risk factor for heart disease, contributing to one out of every three deaths. Traditional pathways for cardiac screening can involve wait times of up to two months for an appointment and even longer for test results. HeartSecure addresses these delays by providing immediate, at-home results, significantly improving accessibility and timeliness in cardiac care.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTCY:
- Is BTCY a Buy, Before Earnings?
- Biotricity launches HeartSecure direct-to-consumer screening service
- Biotricity sees 2024 revenue growth exceeding 24% year-over-year
- Biotricity to launch direct-to-patient cardiac screening service HeartSecure
- Biotricity files to sell 1.42M shares of common stock for holders
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue